ImmuCell Corporation (ICCC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ImmuCell Corporation (ICCC) has a cash flow conversion efficiency ratio of 0.123x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.57 Million) by net assets ($29.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ICCC net asset quality index to measure how much of total assets are equity-financed.
ImmuCell Corporation - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how ImmuCell Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ICCC operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
ImmuCell Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ImmuCell Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Malindo Feedmill Tbk
JK:MAIN
|
-0.003x |
|
SRV YHTIOET OYJ
F:B7J1
|
N/A |
|
United Bancorp Inc
NASDAQ:UBCP
|
0.005x |
|
Imaflex Inc
V:IFX
|
0.039x |
|
Metro Ticari ve Mali Yatirimlar Holding AS
IS:METRO
|
0.000x |
|
Rich Honour International Designs Co Ltd
TW:6754
|
0.114x |
|
Acset Indonusa Tbk
JK:ACST
|
-0.226x |
|
Bastei Lübbe AG
XETRA:BST
|
-0.015x |
Annual Cash Flow Conversion Efficiency for ImmuCell Corporation (1989–2025)
The table below shows the annual cash flow conversion efficiency of ImmuCell Corporation from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see ICCC market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.06 Million | $2.48 Million | 0.091x | +603.45% |
| 2024-12-31 | $27.52 Million | $357.90K | 0.013x | +106.95% |
| 2023-12-31 | $24.99 Million | $-4.67 Million | -0.187x | -268.02% |
| 2022-12-31 | $30.38 Million | $-1.54 Million | -0.051x | -273.50% |
| 2021-12-31 | $32.58 Million | $954.17K | 0.029x | -37.07% |
| 2020-12-31 | $28.27 Million | $1.32 Million | 0.047x | +477.85% |
| 2019-12-31 | $28.99 Million | $233.51K | 0.008x | +146.90% |
| 2018-12-31 | $21.74 Million | $-373.40K | -0.017x | -134.46% |
| 2017-12-31 | $23.59 Million | $1.18 Million | 0.050x | +403.43% |
| 2016-12-31 | $19.72 Million | $-323.90K | -0.016x | -106.01% |
| 2015-12-31 | $10.61 Million | $2.90 Million | 0.273x | +736.69% |
| 2014-12-31 | $9.26 Million | $302.36K | 0.033x | -72.07% |
| 2013-12-31 | $9.40 Million | $1.10 Million | 0.117x | +212.19% |
| 2012-12-31 | $9.19 Million | $344.39K | 0.037x | +1005.44% |
| 2011-12-31 | $9.02 Million | $-37.31K | -0.004x | +95.25% |
| 2010-12-31 | $9.28 Million | $-808.61K | -0.087x | -664.32% |
| 2009-12-31 | $9.62 Million | $-109.67K | -0.011x | -306.85% |
| 2008-12-31 | $9.64 Million | $53.14K | 0.006x | -84.15% |
| 2007-12-31 | $10.06 Million | $349.56K | 0.035x | -76.12% |
| 2006-12-31 | $9.33 Million | $1.36 Million | 0.146x | +62.84% |
| 2005-12-31 | $8.56 Million | $764.78K | 0.089x | -49.14% |
| 2004-12-31 | $7.73 Million | $1.36 Million | 0.176x | -7.76% |
| 2003-12-31 | $7.37 Million | $1.40 Million | 0.190x | -30.22% |
| 2002-12-31 | $6.95 Million | $1.90 Million | 0.273x | +82.16% |
| 2001-12-31 | $6.05 Million | $906.00K | 0.150x | +918.37% |
| 2000-12-31 | $5.54 Million | $81.50K | 0.015x | -93.90% |
| 1999-12-31 | $2.82 Million | $679.70K | 0.241x | -11.48% |
| 1998-12-31 | $2.20 Million | $600.00K | 0.273x | +527.27% |
| 1997-12-31 | $2.30 Million | $100.00K | 0.043x | +182.61% |
| 1996-12-31 | $1.90 Million | $-100.00K | -0.053x | -133.33% |
| 1995-12-31 | $1.90 Million | $300.00K | 0.158x | +400.00% |
| 1994-12-31 | $1.90 Million | $-100.00K | -0.053x | -221.05% |
| 1993-12-31 | $2.30 Million | $100.00K | 0.043x | +126.09% |
| 1992-12-31 | $1.80 Million | $-300.00K | -0.167x | +79.17% |
| 1991-12-31 | $1.50 Million | $-1.20 Million | -0.800x | -348.00% |
| 1990-12-31 | $2.80 Million | $-500.00K | -0.179x | -1.19% |
| 1989-12-31 | $3.40 Million | $-600.00K | -0.176x | -- |
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavir… Read more